Literature DB >> 11998893

Genetic instability of adult T-cell leukemia/lymphoma by comparative genomic hybridization analysis.

Kunhiro Tsukasaki1.   

Abstract

Adult T-cell leukemia/lymphoma (ATL) is a distinct clinicopathological entity, i.e., peripheral T-lymphocytic malignancy caused by human T-lymphotropic virus type I (HTLV-1) with diverse clinical features. High frequency of genetic instability (GIN) in both aggressive and indolent ATL was detected by comparative genomic hybridization (CGH). Among GIN, chromosomal instability, i.e., ancuploidy, in indolent ATL was as frequent but less complex and dynamic as compared to those in aggressive ATL. Some of the CGH alterations, including gain of 14q32, appear to be rather ATL specific. Clonal instability of HTLV-1-infected T cells. i.e., emergence of distinct clone, was detected in about one forth of acute crisis from indolent ATL by CGH and Southern blotting for HTLV-1. Taking together with the previous reports of frequent subtle mutations in several tumor suppressor genes in aggressive ATL, GIN in multistep leukemogenesis of ATL is diverse including clonal, chromosomal, and nucleotide levels.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11998893     DOI: 10.1023/a:1014471500757

Source DB:  PubMed          Journal:  J Clin Immunol        ISSN: 0271-9142            Impact factor:   8.317


  30 in total

1.  Prognostic significance of the proportion of Ki-67-positive cells in adult T-cell leukemia.

Authors:  Y Yamada; K Murata; S Kamihira; S Atogami; K Tsukasaki; H Sohda; T Yanagisako; S Momita; T Jubashi; T Amagasaki
Journal:  Cancer       Date:  1991-05-15       Impact factor: 6.860

2.  Chromosomal imbalances in adult T-cell leukemia revealed by comparative genomic hybridization: gains at 14q32 and 2p16-22 in cell lines.

Authors:  Y Ariyama; T Mori; T Shinomiya; T Sakabe; Y Fukuda; A Kanamaru; Y Yamada; M Isobe; M Seto; Y Nakamura; J Inazawa
Journal:  J Hum Genet       Date:  1999       Impact factor: 3.172

Review 3.  Comparative genomic hybridization: an overview.

Authors:  J Houldsworth; R S Chaganti
Journal:  Am J Pathol       Date:  1994-12       Impact factor: 4.307

4.  Mutations in the mitotic check point gene, MAD1L1, in human cancers.

Authors:  K Tsukasaki; C W Miller; E Greenspun; S Eshaghian; H Kawabata; T Fujimoto; M Tomonaga; C Sawyers; J W Said; H P Koeffler
Journal:  Oncogene       Date:  2001-05-31       Impact factor: 9.867

5.  Integration patterns of HTLV-I provirus in relation to the clinical course of ATL: frequent clonal change at crisis from indolent disease.

Authors:  K Tsukasaki; H Tsushima; M Yamamura; T Hata; K Murata; T Maeda; S Atogami; H Sohda; S Momita; S Ideda; S Katamine; Y Yamada; S Kamihira; M Tomonaga
Journal:  Blood       Date:  1997-02-01       Impact factor: 22.113

Review 6.  Human T-lymphotropic virus type 1 infection.

Authors:  K Tsukasaki; P Koeffler; M Tomonaga
Journal:  Baillieres Best Pract Res Clin Haematol       Date:  2000-06

7.  Cytogenetic and molecular characterization of random chromosomal rearrangements activating the drug resistance gene, MDR1/P-glycoprotein, in drug-selected cell lines and patients with drug refractory ALL.

Authors:  T Knutsen; L A Mickley; T Ried; E D Green; S du Manoir; E Schröck; M Macville; Y Ning; R Robey; M Polymeropoulos; R Torres; T Fojo
Journal:  Genes Chromosomes Cancer       Date:  1998-09       Impact factor: 5.006

8.  Chromosome abnormalities in adult T-cell leukemia/lymphoma: a karyotype review committee report.

Authors:  N Kamada; M Sakurai; K Miyamoto; I Sanada; N Sadamori; S Fukuhara; S Abe; Y Shiraishi; T Abe; Y Kaneko
Journal:  Cancer Res       Date:  1992-03-15       Impact factor: 12.701

9.  Mutations of the p53 gene in adult T-cell leukemia.

Authors:  A Sakashita; T Hattori; C W Miller; H Suzushima; N Asou; K Takatsuki; H P Koeffler
Journal:  Blood       Date:  1992-01-15       Impact factor: 22.113

10.  Detection and isolation of type C retrovirus particles from fresh and cultured lymphocytes of a patient with cutaneous T-cell lymphoma.

Authors:  B J Poiesz; F W Ruscetti; A F Gazdar; P A Bunn; J D Minna; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  1980-12       Impact factor: 11.205

View more
  6 in total

1.  Expression profiles of adult T-cell leukemia-lymphoma and associations with clinical responses to zidovudine and interferon alpha.

Authors:  Ash A Alizadeh; Sean P Bohen; Chen Lossos; Jose A Martinez-Climent; Juan Carlos Ramos; Elena Cubedo-Gil; William J Harrington; Izidore S Lossos
Journal:  Leuk Lymphoma       Date:  2010-07

Review 2.  T-cell control by human T-cell leukemia/lymphoma virus type 1.

Authors:  Genoveffa Franchini; Risaku Fukumoto; Jake R Fullen
Journal:  Int J Hematol       Date:  2003-11       Impact factor: 2.490

Review 3.  Updates in lymph node and skin pathology of adult T-cell leukemia/lymphoma, biomarkers, and beyond.

Authors:  Brian D Adkins; Juan C Ramos; Meghan Bliss-Moreau; Alejandro A Gru
Journal:  Semin Diagn Pathol       Date:  2019-12-20       Impact factor: 3.464

4.  Genomic instability and rapid clinical course in adult T-cell lymphoma/leukemia patient.

Authors:  Adriana Zámecníkova; Soad Al Bahar; Samah E Elshinnawy
Journal:  Leuk Res       Date:  2010-03-07       Impact factor: 3.156

5.  Epstein-Barr virus DNase (BGLF5) induces genomic instability in human epithelial cells.

Authors:  Chung-Chun Wu; Ming-Tsan Liu; Yu-Ting Chang; Chih-Yeu Fang; Sheng-Ping Chou; Hsin-Wei Liao; Kuan-Lin Kuo; Shih-Lung Hsu; Yi-Ren Chen; Pei-Wen Wang; Yu-Lian Chen; Hsin-Ying Chuang; Chia-Huei Lee; Ming Chen; Wun-Shaing Wayne Chang; Jen-Yang Chen
Journal:  Nucleic Acids Res       Date:  2009-12-23       Impact factor: 16.971

6.  Ectonucleotidase CD39 is highly expressed on ATLL cells and is responsible for their immunosuppressive function.

Authors:  Yasuhiro Nagate; Sachiko Ezoe; Jiro Fujita; Daisuke Okuzaki; Daisuke Motooka; Tomohiko Ishibashi; Michiko Ichii; Akira Tanimura; Masako Kurashige; Eiichi Morii; Takuya Fukushima; Youko Suehiro; Takafumi Yokota; Hirohiko Shibayama; Kenji Oritani; Yuzuru Kanakura
Journal:  Leukemia       Date:  2020-03-20       Impact factor: 11.528

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.